Study Confirms Benefit of Regorafenib in Previously Treated Metastatic Colorectal Cancer
the ONA take:
According to research presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have confirmed that regorafenib is beneficial for the treatment of patients with previously treated metastatic colorectal cancer.
The phase III CORRECT study previously demonstrated a significant improvement in progression-free survival in patients with previously treated metastatic colorectal cancer. For the phase IIIb CONSIGN trial, researchers prospectively assessed the efficacy and safety of regorafenib in patients with pre-treated metastatic colorectal cancer before marketing of the drug was authorized.
The study showed that the estimated progression-free survival was 2.7 months and there were no surprising findings in regard to adverse events.
The CONSIGN trial is significant in that its patient population more closely resembled a real world population of patients compared with the CORRECT trial
"CONSIGN confirms the efficacy and safety data of the randomised phase III CORRECT and CONCUR trials. The merit of CONSIGN is that it translates phase III data into the clinical routine since patients had similar characteristics and pre-treatment to what we see in daily practice," Dirk Arnold, MD, ESMO spokesperson, director of the Department of Medical Oncology, Klinik für Tumorbiologie in Freiburg, Germany, said.
Researchers have confirmed that regorafenib is effective for the treatment of previously treated metastatic colorectal cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|